{"id":4514,"date":"2021-02-22T16:28:53","date_gmt":"2021-02-22T16:28:53","guid":{"rendered":"http:\/\/lonecandle.com\/?p=4514"},"modified":"2021-02-22T16:28:53","modified_gmt":"2021-02-22T16:28:53","slug":"why-we-cant-make-vaccine-doses-any-faster","status":"publish","type":"post","link":"https:\/\/lonecandle.com\/?p=4514","title":{"rendered":"Why We Can\u2019t Make Vaccine Doses Any Faster"},"content":{"rendered":"\n

\n\n“Vaccine supply chains are extremely specialized and sensitive, relying on expensive machinery, highly trained staff and finicky ingredients. Manufacturers have run into intermittent shortages of key materials, according to the U.S. Government Accountability Office<\/a>; the combination of surging demand and workforce disruptions from the pandemic has caused delays of four to 12 weeks for items that used to ship within a week, much like what happened when consumers were sent scrambling for household staples like flour<\/a>, chicken wings<\/a> and toilet paper<\/a>.
<\/p>\n\n\n\n

People often question why the administration can\u2019t use the mighty Defense Production Act \u2014 which empowers the government to demand critical supplies before anyone else \u2014 to turbocharge production. But that law has its limits. Each time a manufacturer adds new equipment or a new raw materials supplier, they are required to run extensive tests to ensure the hardware or ingredients consistently work as intended, then submit data to the Food and Drug Administration. Adding capacity \u201cdoesn\u2019t happen in a blink of an eye,\u201d said Jennifer Pancorbo, director of industry programs and research at North Carolina State University\u2019s Biomanufacturing Training and Education Center. \u201cIt takes a good chunk of weeks.\u201d<\/p>\n\n\n\n

And adding supplies at any one point only helps if production can be expanded up and down the entire chain. \u201cThousands of components may be needed,\u201d said Gerald W. Parker, director of the Pandemic and Biosecurity Policy Program at Texas A&M University\u2019s Scowcroft Institute for International Affairs and a former senior official in the Department of Health and Human Services office for preparedness and response. \u201cYou can\u2019t just turn on the Defense Production Act and make it happen.\u201d<\/p>\n\n\n\n

The U.S. doesn\u2019t have spare facilities waiting around to manufacture vaccines, or other kinds of factories that could be converted the way General Motors began producing ventilators<\/a> last year. The GAO said the Army Corps of Engineers is helping to expand existing vaccine facilities, but it can\u2019t be done overnight.<\/p>\n\n\n\n

Building new capacity would take two to three months, at which point the new production lines would still face weeks of testing to ensure they were able to make the vaccine doses correctly before the companies could start delivering more shots.”<\/p>\n\n\n\n

…<\/p>\n\n\n\n

“The Trump administration deployed the Defense Production Act\u00a0last year<\/a>\u00a0to give vaccine manufacturers priority in accessing crucial production supplies before anyone else could buy them. And the Biden administration used it to help Pfizer obtain specialized needles that can squeeze a sixth dose from the company\u2019s vials, as well as for two critical manufacturing components: filling pumps and tangential flow filtration units.”<\/p>\n\n\n\n

https:\/\/www.propublica.org\/article\/covid-vaccine-supply<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

“Vaccine supply chains are extremely specialized and sensitive, relying on expensive machinery, highly trained staff and finicky ingredients. Manufacturers have run into intermittent shortages of key materials, according to the U.S. Government Accountability Office; the combination of surging demand and workforce disruptions from the pandemic has caused delays of four to 12 weeks for items that used to ship within a week, much like what happened when consumers were sent scrambling for household staples like flour, chicken wings and toilet paper.<\/p>\n

People often question why the administration can\u2019t use the mighty Defense Production Act \u2014 which empowers the government to demand critical supplies before anyone else \u2014 to turbocharge production. But that law has its limits. Each time a manufacturer adds new equipment or a new raw materials supplier, they are required to run extensive tests to ensure the hardware or ingredients consistently work as intended, then submit data to the Food and Drug Administration. Adding capacity \u201cdoesn\u2019t happen in a blink of an eye,\u201d said Jennifer Pancorbo, director of industry programs and research at North Carolina State University\u2019s Biomanufacturing Training and Education Center. \u201cIt takes a good chunk of weeks.\u201d<\/p>\n

And adding supplies at any one point only helps if production can be expanded up and down the entire chain. \u201cThousands of components may be needed,\u201d said Gerald W. Parker, director of the Pandemic and Biosecurity Policy Program at Texas A&M University\u2019s Scowcroft Institute for International Affairs and a former senior official in the Department of Health and Human Services office for preparedness and response. \u201cYou can\u2019t just turn on the Defense Production Act and make it happen.\u201d<\/p>\n

The U.S. doesn\u2019t have spare facilities waiting around to manufacture vaccines, or other kinds of factories that could be converted the way General Motors began producing ventilators last year. The GAO said the Army Corps of Engineers is helping to expand existing vaccine facilities, but it can\u2019t be done overnight.<\/p>\n

Building new capacity would take two to three months, at which point the new production lines would still face weeks of testing to ensure they were able to make the vaccine doses correctly before the companies could start delivering more shots.”<\/p>\n

…<\/p>\n

“The Trump administration deployed the Defense Production Act last year to give vaccine manufacturers priority in accessing crucial production supplies before anyone else could buy them. And the Biden administration used it to help Pfizer obtain specialized needles that can squeeze a sixth dose from the company\u2019s vials, as well as for two critical manufacturing components: filling pumps and tangential flow filtration units.”<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[13],"tags":[588,409,483,925],"class_list":["post-4514","post","type-post","status-publish","format-standard","hentry","category-article-share","tag-corona","tag-coronavirus","tag-covid-19","tag-vaccine"],"_links":{"self":[{"href":"https:\/\/lonecandle.com\/index.php?rest_route=\/wp\/v2\/posts\/4514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lonecandle.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lonecandle.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lonecandle.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lonecandle.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4514"}],"version-history":[{"count":1,"href":"https:\/\/lonecandle.com\/index.php?rest_route=\/wp\/v2\/posts\/4514\/revisions"}],"predecessor-version":[{"id":4515,"href":"https:\/\/lonecandle.com\/index.php?rest_route=\/wp\/v2\/posts\/4514\/revisions\/4515"}],"wp:attachment":[{"href":"https:\/\/lonecandle.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lonecandle.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lonecandle.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}